Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus  by Huang, Shiang-Fen et al.
+ MODEL
Journal of Microbiology, Immunology and Infection (2015) xx, 1e9Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEEffects of corticosteroid and neuraminidase
inhibitors on survival in patients with
respiratory distress induced by influenza
virus
Shiang-Fen Huang a,b,c, Chang-Phone Fung a,
Diahn-Warng Perng d, Fu-Der Wang a,b,*a Division of Infectious Disease, Department of Medicine, Taipei Veterans General Hospital, Taipei,
Taiwan
b School of Medicine, National Yang-Ming University, Taipei, Taiwan
c Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
d Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, TaiwanReceived 14 May 2015; received in revised form 20 August 2015; accepted 25 August 2015





peramivir* Corresponding author. Division of In
Shih-Pai Road, Taipei, Taiwan.
E-mail address: fdwang@vghtpe.go
Please cite this article in press as: H
respiratory distress induced by influ
j.jmii.2015.08.016
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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: Neuraminidase inhibitors (NAIs) including oseltamivir and
peramivir are used for influenza treatment. A systemic corticosteroid is usually administrated
for acute respiratory distress syndrome. The aim of this study was to investigate the effect of a
systemic corticosteroid and its interaction with NAIs in patients with influenza infection and
respiratory distress.
Methods: A retrospective survey of hospitalized patients infected with influenza from January
2012 to May 2014 was conducted in a medical center in Taiwan.
Results: Eighty-six patients were hospitalized during the study period. Forty-eight patients had
respiratory distress and 39 of them (81.3%, 39/48) were supported by a mechanical ventilator.
All patients with respiratory distress received oseltamivir; 60.4% (29/48) and 31.3% (15/48) of
them received a corticosteroid and salvage intravenous peramivir, respectively. All-cause mor-
tality was 29.1% (14/48), 20% (3/15), and 31% (9/29) in patients with respiratory distress, pa-
tients who received salvage peramivir, and patients who received a systemic corticosteroid,
respectively. Salvage peramivir seemed to improve prognosis in patients with H1pdm09 or type
B virus infection and respiratory distress (pZ 0.05). Early initiating corticosteroid had a worse
prognosis than initiation after 72 hours of NAI treatment (pZ 0.024). In particular, a systemicfectious Disease, Department of Medicine, Taipei Veterans General Hospital, Number 201, Section 2,
v.tw (F.-D. Wang).
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(p Z 0.05).
Conclusion: Salvage peramivir provided a better prognosis than monotherapy with oseltamivir
in patients who were infected with H1pdm09 or type B virus and who developed respiratory
distress. A systemic corticosteroid should be administered after initiating NAI therapy, espe-
cially in patients with chronic lung disease.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The pandemic H1pdm09 virus spread in 2009 and has been
prevalent since 2011. Clinical trials investigating the early
use of multidose intravenous peramivir against seasonal
influenza including H1N1, H3N2, and type B viruses showed
similar outcomes to daily oseltamivir.1,2 Intravenous per-
amivir was shown to be effective for the influenza virus
infection with the H275Y mutant strain.3 Emergency use of
peramivir has been authorized in the USA since 20094 ac-
cording to the high morbidities and morbidities related to
H1N1 (2009) infection. After 2009, only a few reports on the
treatment outcomes of peramivir against H1N1pdm09-
related infection have been published,1,5e7 and recent
data regarding the clinical outcomes of salvage peramivir
for influenza infection with respiratory distress is lacking.
Meanwhile, the benefits of medium-to-high doses of
corticosteroid in patients with influenza virus infection and
acute respiratory distress syndrome remain controversial.8
Despite the facts that a corticosteroid is not recom-
mended by some guidelines,9 it remains standard treatment
for physicians working in critical care units to treat acute
respiratory distress syndrome10 after influenza infection.
The newly emerged mutant H275Y strain has been
detected in Taiwan,11 and the use of peramivir was
authorized by the Center of Disease and Infection of Taiwan
in late 2013 for patients with severe illness who do not
respond to oseltamivir. In this study, we aimed to investi-
gate retrospectively clinical outcomes among patients
hospitalized with influenza virus infection from 2012 to
2014 in northern Taiwan, and to assess the interaction be-
tween two types of neuraminidase inhibitors (NAIs) and
administration of a systemic corticosteroid.
Methods
Patients
Patients with laboratory confirmed influenza virus infection
from January 1, 2012 to May 31, 2014 in Taipei Veterans
General Hospital, Taipei, Taiwan were assessed retrospec-
tively by chart review. Only patients who were older than
18 years and hospitalized were included. Patients with
hospital acquired influenza virus infection and contact
history were excluded. Clinical characteristics, comorbid-
ities, chest radiography results, laboratory results, and
clinical outcome were recorded.uang S-F, et al., Effects of cortic
enza virus, Journal of MicrobiologLaboratory confirmation of influenza virus
Confirmation of influenza infection was performed by using
a rapid influenza antigen test (Directigen EZ Flu AþB test;
BD, Franklin Lakes, NJ, USA) or real-time reverse-tran-
scription polymerase chain reaction (RT-PCR). The primers
and Taqman probes used for RT-PCR were those reported in
the standard protocol of the Center of Disease Control of
Taiwan, which was modified from that of the World Health
Organization.11e13 This protocol includes primers for the
matrix gene of influenza A and B viruses, as well as the
hemagglutinin gene of influenza A viruses (seasonal H1,
H1pdm09, and H3 primers). If the presence of influenza A
virus was detected, a further genotype was identified ac-
cording to the RT-PCR results, i.e., seasonal H1, H1pdm09,
or H3; otherwise, unidentified influenza A was recorded.
Medical treatment
The antiviral treatments were according to the manufac-
turer’s guidance: 5 mg of zanamivir powder was inhaled
twice daily for 5 days, or 75 mg of oral oseltamivir was given
daily for 5 days. Intravenous peramivir was prescribed as
300e600 mg (adjusted by creatinine clearance rate) per 12
hours for at least 3 days, and extended to 5e10 days if
clinical symptoms were not completely resolved. Medium-
to-high dose corticosteroid was defined as systemic
administration of a dose  0.5e2 mg/kg/d.
Clinical manifestations and outcomes
Respiratory distress was defined as desaturation with a
ratio of partial pressure arterial oxygen and fraction of
inspired oxygen (PaO2/FiO2) of < 200 mmHg or an oxygen
saturation (SaO2) < 90% with a FiO2 > 50%. The incidence of
organ dysfunction including shock, hematological abnor-
mality (white blood cell count of >10,000 cells/mm3
or < 4000 cells/mm3, or thrombocytopenia of < 8000 cells/
mm3), respiratory distress, acute disturbance of con-
sciousness levels, acute renal distress with renal replace-
ment therapy, and hepatic failure with decomposition was
recorded. The metabolic syndrome was defined according
to the World Health Organization14 and included type 2
diabetes, hyperlipidemia or hypercholesterolemia, cardio-
vascular disease (including hypertension), and obesity
(body mass index > 30 kg/cm2). Late onset superinfection
and colonization were defined as laboratory evidence ofosteroid and neuraminidase inhibitors on survival in patients with
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Table 1 Genotypes of influenza virus detected by
real-time reverse-transcription polymerase chain reaction




H3 10 4 (50) 1 (20) 5 (6.8)
Seasonal H1 5 2 (40) 3 (4.1)
H1pdm09 26 26 (35.6)
Seasonal
H1þH1pdm09a
25 1 (20) 24 (32.9)
Unidentifiedb 13 1 (20) 12 (16.4)
Influenza B 7 4 (50) 3 (4.1)
Total 86 8 5 73
a The results of RT-PCR showed double positive for seasonal
H1 and H1pdm09 genetic sequence.
b Influenza A with genotypes other than H1 or H3.
Data are presented as n (%).
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cheal aspiration or sputum with adequate sampling, or by
the presence of laboratory evidence from a sterile site
(e.g., blood culture) after 72 hours of hospitalization.
Statistical analysis
Continuous data were compared with the Student t test or a
nonparametric test if they were not normally distributed.
Categorical results were compared with the Pearson Chi-
square test or Fisher’s exact test if the excepted number
was < 5. Odds ratios with 95% confidence intervals (95% CIs)
were obtained. Survival analysis was performed using the
KaplaneMeier method and nonparametric tests were used
to analyze differences. A p value < 0.05 was defined as
significant.
Ethics statement
The informed consent was waved in this retrospective study
by approval from the Ethics Committee of Taipei Veterans
General Hospital (VGHIRB No:2014-05-001BC).
Results
Genotypes
Eighty-six hospitalized patients older than 18 years were
enrolled. The influenza viral genotypes are demonstrated in
Table 1. Type A viruses were predominant (91.8%, 79/86)
during the study period. Furthermore, 30.2% of patients had
the type A H1pdm09 strain, and 29.1% of patients had both
seasonal H1 and H1pdm09 from 2012 to 2014.
Patient characteristics
The clinical characteristics of the study participants are
demonstrated in Table 2. In the 86 hospitalized patients,
the mean age was 65.9 years (standard deviation: 19.2
years), and more patients were male (65%, 56/86). With
regards to comorbidities, 25.6% of patients had chronic lung
disease, 30.2% had congestive heart failure, 23.3% had
cardiovascular disease, and 43.0% had diabetes.
Clinical manifestations
Virology results showed that 64.6% of the patients with
respiratory distress were infected with H1pdm09. Clini-
cally, more than half of the patients (55.8%, 48/86) suf-
fered from respiratory distress; 81.3% (39/48) of these
patients were supported by mechanical ventilation. The
second most frequent clinical manifestation was acute
kidney injury (52.3%, 45/86), followed by shock (34.9%, 30/
86), gastrointestinal bleeding (30.2%, 26/86), and acute
myocardial infarction (9%, 8/86).
Acute kidney injury (64.6%), shock (58.3%), and the
requirement for hemodialysis (20.8%) developed more
frequently in patients with respiratory distress than in pa-
tients without respiratory distress (p < 0.05). A total of 20%Please cite this article in press as: Huang S-F, et al., Effects of cortic
respiratory distress induced by influenza virus, Journal of Microbiolog
j.jmii.2015.08.016of the patients were supported with extracorporeal mem-
brane oxygenation.
Clinical outcomes
The all-cause mortality rate was 29.1% among patients with
respiratory distress; this rate was higher in patients older
than 65 years (43.5%, p < 0.05) and those with chronic lung
disease (46.2%, p < 0.05; Table 3). The influenza genotype,
types of NAI, and time to administration of systemic corti-
costeroid were not associated with all-cause mortality in
patients with respiratory distress (p > 0.05; Table 3).
The mean hospital stay in patients with respiratory
distress was 27.6 days (95% CI: 22.233.1 days), and none
of the patients without respiratory distress died in hospital.
Survival analysis showed that among the patients with
respiratory distress, the H1pdm09 and type B viruses
seemed to be more virulent, with a worse prognosis
compared to the other type A viruses (Figure S1).
The median length of ventilator support was 11.0 days
(mean: 19.2 days, 95% CI: 11.826.6 days) and patients
with chronic lung disease had a longer period of ventilator
support (mean: 36.8 days, 95% CI: 16.157.6 days,
pZ 0.12). Administration of a corticosteroid, types of NAI,
and other factors including age and gender were not
related to the length of ventilator support.
NAIs and corticosteroid
All patients with respiratory distress received oral oselta-
mivir. Of the patients studied, 39.3% received intravenous
peramivir, either sequentially (14.3%) or overlapping (25%)
with oseltamivir (Table 2). Among the patients with respi-
ratory distress who were infected with influenza H1pdm09
or type B viruses, salvage peramivir (mortality rate: 10%, 1/
10) had a better prognosis than monotherapy with oselta-
mivir (mortality rate: 44%, 11/25; Figure 1). In these pa-
tients, one of the nine patients treated with salvage
peramivir who also received a systemic corticosteroid died
in hospital, and the systemic corticosteroid only improvedosteroid and neuraminidase inhibitors on survival in patients with
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Table 2 Characteristics of adult patients with influenza virus infection during 2012e2014.
Subtotal Respiratory distress p*
No Yes
Gender
Male 56 27 (71.1) 30 (62.5)
Female 30 11 (28.9) 18 (37.5)
Age (y)
 65 39 14 (36.8) 25 (52.1) 0.074
> 65 47 24 (63.2) 23 (47.9)
Comorbidities
Cardiovascular disease 20 10 (26.3) 10 (20.8)
Congestive heart failure 26 9 (23.7) 17 (35.4)
Chronic pulmonary disease 22 9 (23.7) 13 (27.1)
Chronic kidney disease stage IIIeIV 20 8 (21.1) 12 (25.0)
Chronic hepatic disease 10 2 (5.3) 8 (16.7) 0.09
Neurological/neuromuscular disease 19 11 (28.9) 8 (16.7)
Diabetes 37 15 (39.5) 22 (45.8) 0.011
Hyperlipidemia/hypercholesterolemia 12 9 (23.7) 3 (6.3)
Obesity (BMI > 30)a 6 5 (13.1) 1 (2.1) 0.07
Metabolic syndrome 47 22 (64.7) 25 (53.2)
Immunosuppression 30 14 (36.8) 16 (33.3)
Hematologic disorders 8 3 (7.9) 5 (10.4)
Solid organ malignancy 9 4 (10.5) 5 (10.4)
Clinical manifestation
Acute kidney injury 45 14 (36.8) 31 (64.6) 0.027
Acute myocardial infarction 8 2 (5.3) 6 (12.5)
Gastrointestinal bleeding 26 9 (23.7) 17 (35.4)
Hepatic failure 4 0 4 (8.3)
Shock 30 2 (5.3) 28 (58.3) < 0.01
Mechanical ventilation 39 0 39 (81.3) < 0.01
Extracorporeal membrane oxygenation (ECMO) 10 0 10 (20.8) < 0.01
Hemodialysis 12 2 (5.3) 10 (20.8) 0.039
No. of organ failures  1 49 38 (100) 11 (22.9)
No. of organ failures  2 37 0 37 (77.1)
Influenza rapid test
Positive 42 25 (65.8) 17 (35.4) 0.002
Negative 37 8 (21.1) 29 (60.4)
NA 7 5 (13.2) 2 (4.2)
Influenza genotype
Type A 79 35 (92.1) 44 (91.7)
With H1pdm09 51 20 (52.6) 31 (64.6)
Without H1pdm09 28 15 (39.4) 13 (27.1)
Type B 7 3 (7.9) 4 (8.3)
Treatmentb 0.016
Zanamivir 6 6 (15.8)
Oseltamivir 79 31 (81.6) 48 (100)
Oseltamivir, peramiviresequential 7 0 7 (14.5)
Oseltamivir, peramivirecombined or overlap 8 0 8 (16.7)
Administration of systemic corticosteroid 33 6 (15.8) 27 (56.3) < 0.01
Total 86 38 (100) 48 (100)
a The data regarding to height was unavailable in six patients.
b One patient did not receive neuraminidase inhibitor treatment.
Data are presented as n (%).
*The p values were shown when the probability was significantly different (p < 0.05) between patients with or without respiratory
failure.
BMI Z body mass index; NA Z Not available.
4 S.-F. Huang et al.
+ MODEL
Please cite this article in press as: Huang S-F, et al., Effects of corticosteroid and neuraminidase inhibitors on survival in patients with
respiratory distress induced by influenza virus, Journal of Microbiology, Immunology and Infection (2015), http://dx.doi.org/10.1016/
j.jmii.2015.08.016
Table 3 All-cause mortality in patients with influenza infection and respiratory distress.
Variable N All-cause mortality Hospital LOS (d) p**
Gender
Male 30 10 (33.3) 26.9 (19.9e33.9)
Female 18 4 (22.2) 28.1 (16.839.3)
Age (y)
 65 25 4 (16) 22.9 (16.629.3)
> 65 23 10 (43.5)* 32.8 (22.443.2)
Immune status
Immunocompetent 32 8 (25.0) 26.7 (19.933.5)
Immunocompromised 16 6 (37.5) 29.8 (16.241.5)
Malignancy 9 3 (33.3) 32.3 (10.853.6)
Chronic lung disease 13 6 (46.2)* 30.0 (19.340.7)
Diabetes 22 9 (40.9) 27.7 (18.137.4)
Obesity (BMI > 30) 6 0 21.0 (3.238.7)
Metabolic syndrome
No 22 4 (18) 27.0 (18.735.4)
Yes 25 10 (40) 27.6 (19.036.1) 0.09
No. of organ failures  1 11 0 17.9 (10.824.9)
No. of organ failures  2 37 14 (37.8) 30.0 (23.037.1)
Corticosteroid
No 19 5 (26.3) 25.7 (14.137.0)
Yes 29 9 (31.0) 29.0 (23.334.7)
Before & within 72 h of NAIs 17 7 (41.2) 20.9 (11.130.7)a 0.02
After72 h of NAIs 12 2 (16.7) 34.5 (20.348.6)
Short-term use ( 3 d) 4 0 (0) 36.3 (11.130.7)
Continuous use for 4e13 d 14 9 (64.2) 26.1 (8.233.9)
Continuous use for  14 d 10 4 (40%) 32.3 (20.544.0)
Influenza virus genotype
Type A 44 12 (27.2) 27.9 (22.133.8)
With H1pdm09 31 10 (32.2) 25.0 (19.630.6)
Without H1pdm09 13 2 (15.3) 34.7 (8.750.8)
Type B 4 2 (50) 24.5 (4.744.2)
Neuraminidase inhibitors
Oseltamivir monotherapy 33 11 (33.3) 26.1 (18.933.2)
Oseltamivir & peramivir
Sequential 7 1 (14.3) 33.2 (16.450.1)
Combine/overlap 8 2 (25.0) 29.3 (17.341.2)
Total 48 14 (29.1) 27.6 (22.233.1)
a Compared with corticosteroid use after 72 hours of antiviral treatment.
Data are presented as n (%) or mean (95% CI).
*p < 0.05 by the Chi-square test.
**p < 0.05 was shown by the log-rank test in KaplaneMeier analysis.
BMI Z body mass index; CI Z confidence intervals; LOS Z length of stay; NAIs Z neuraminidase inhibitors.
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overall prognosis. By contrast, patients who received osel-
tamivir had the worst prognosis and this was unrelated to
the systemic corticosteroid.
Regarding the time to initiation of corticosteroid, pa-
tients who received early systemic corticosteroid prior to or
within 72 hours of effective NAIs had a poorer prognosis
when compared to those who received a corticosteroid 72
hours after the initiation of NAIs (p Z 0.02; Figure 2).
Chronic lung disease
Thirteen patients with chronic lung disease and respiratory
distress were selected for subgroup analysis. The all-cause
mortality was not related to administration of salvagePlease cite this article in press as: Huang S-F, et al., Effects of cortic
respiratory distress induced by influenza virus, Journal of Microbiolog
j.jmii.2015.08.016peramivir or not (3/6 vs. 3/7, p > 0.05). In addition, the
types of NAI used did not affect the length of hospital stay
(Figure S3). Among them, 10 received a corticosteroid with
all-cause mortality of 60% (6/10). Systemic corticosteroid
was a poor prognosis factor for overall survival (p Z 0.05;
Figure 3). Of the six patients who died, five had received a
corticosteroid prior to or within 72 hours of effective NAI,
and the other patient died in hospital when he received a
corticosteroid after 72 hours of an effective NAI.
Metabolic syndrome
There were 37 patients without chronic lung disease but
with metabolic syndrome. Among them, 18 patients
developed respiratory distress, and the all-cause mortalityosteroid and neuraminidase inhibitors on survival in patients with
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Figure 1. Survival analysis for patients infected with
H1pdm09 or type B virus and with respiratory distress, strati-
fied by types of neuraminidase inhibitors (p Z 0.05, Log-rank
test).
Figure 3. Survival analysis for patients with chronic lung
disease who developed respiratory distress. The analysis was
stratified by administration of a systemic corticosteroid
(p Z 0.05; Log-rank test).
Table 4 Superinfection and colonization in sputa of pa-
tients with respiratory distress and mechanical ventilation.
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compared to zero mortality (0/6) in those who received
salvage peramivir (0/6, p Z 0.1) therapy. The all-cause
mortality in patients who developed respiratory distress
and received a corticosteroid was 16.6% (1/6), compared to
the patients without systemic corticosteroid (41.6%, 5/12,
p Z 0.3). Three patients received a corticosteroid prior to
or within 72 hours of effective NAIs and one died in hospi-
tal. The median lengths of hospital stay were 25 (Inter-
quartile Range: 33.7) and 12.5 (IQR: 11) days in patients
with or without systemic corticosteroid, respectively,
(p > 0.05; Figure S4).Figure 2. Survival analysis in patients with influenza infec-
tion and respiratory distress. The survival functions were
stratified by prescribing a systemic corticosteroid before or
within 72 hours (early) and after 72 hours (late) of initiation of
antiviral therapy (p Z 0.02; Log-rank test).
Please cite this article in press as: Huang S-F, et al., Effects of cortic
respiratory distress induced by influenza virus, Journal of Microbiolog
j.jmii.2015.08.016Superinfection and colonization
Late onset superinfection and colonization were more
frequently observed in patients with a hospital stay of > 7
days (53.1% vs. 12.5%, p < 0.05). The colonization or su-
perinfection of Gram-negative bacteria was 19.7% overall
and 33% in patients with respiratory distress. The most
common bacteria isolated were pandrug-resistant or
imipenem-resistant Acinetobacter baumannii (PDRAB orN Hospital LOS






IRAB or PDRAB 6 6 4 2
Acinetobacter baumannii 3 3 3
Pseudomonas aeruginosa 4 1 3 2 1
Corynebacterium species 1 1 1
Enterobacter spp. 1 1 1
Stenotrophomonas spp. 1 1
Not identified 3 1 2 2
Gram-positive bacteria
MRSA 1 1 1
Yeast 3 3 2 1
Subtotal 19 2 * 17 13 4
No bacteria or
normal flora
29 14 15 9 6
Total 48 16 32 22 10
*p < 0.05 when compared with hospital LOS  7 days.
IRAB Z imipenem-resistant Acinetobacter baumannii;
LOS Z length of stay; MRSA Z methicillin-resistant Staphylo-
coccus aureus; PDRAB Z pandrug-resistant Acinetobacter
baumannii.
osteroid and neuraminidase inhibitors on survival in patients with
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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mortality (p Z 0.1) but was marginally associated with
systemic corticosteroid in patients with respiratory distress
[44.8% (13/29) vs. 15.7% (3/19), p Z 0.06].Discussion
This study is the first manuscript to describe salvage per-
amivir treatment in oseltamivir nonresponders during the
flu season from 2012 to 2014 in Taiwan, and the first
investigation regarding the interaction between two NAIs
and a systemic corticosteroid in patients with influenza
infection.
The all-cause mortality was similar to previous findings6
in patients who received peramivir and had severe illness
(20% vs.16%), as well as the proportion of patients who had
previous oseltamivir treatment (31.3% vs. 23%). Further,
virulent influenza viruses, including H1N1pdm09 and type B
viruses, with a poor prognosis were observed in our cohort.
However, the information regarding the H275Y mutation or
NAI susceptibility was lacking because the necessary labo-
ratory facilities were unavailable in the study hospital.
Rapid and effective clinical diagnosis methods allowing the
prediction of NAI susceptibility is warranted.
Aside from oseltamivir provided negligible competitively
inhibition affinity against NA enzyme when combined with
peramivir,15 single peramivir use was found to be partially
effective in oseltamivir-resistant type A influenza infected
mice.16 Combination of peramivir and oseltamivir was
better than the single use of one NAI against influenza
infection.17 Further, in pediatric patients it was shown that
there was no significant difference between early combi-
nation of peramivir with oseltamivir or zanamivir.18
Although a small sample size was enrolled in the current
study, a higher all-cause mortality rate was observed in
patients with respiratory distress who were treated with
overlapping peramivir and oseltamivir (25%, 2/8) when
compared to patients treated with peramivir sequentially
after oseltamivir (14%, 1/7). Further research to increase
the number of cases is suggested.
Clinical trials on the early use of multidose intravenous
peramivir against seasonal influenza including H1N1, H3N2,
and type B viruses have shown similar outcomes to those
with daily oseltamivir.1,2. Recent investigation showed the
benefit of intravenous peramivir within 48 hours of the
onset of symptoms,19 and for treating severe illness,6,20 and
its effectiveness against viruses resistant to oseltamivir has
been proven.21,22 Our results showed that salvage peramivir
was superior to oseltamivir alone for patients infected with
H1pdm09 and type B viruses with respiratory distress. Since
the effectiveness of peramivir was found to be optimal
initiated within the first 48 hours of onset of symptoms, the
early use of intravenous peramivir in order to prevent
further respiratory distress is warranted in Taiwan.
Our results showed that monotherapy with oseltamivir
had the worst prognosis, and it was unrelated to adminis-
tration of a systemic corticosteroid. The co-existence of
peramivir and corticosteroid-sparing treatment might indi-
cate the benefit of peramivir itself. Few patients who
received a corticosteroid and peramivir showed poor
prognosis, but this may be due to selection bias, and furtherPlease cite this article in press as: Huang S-F, et al., Effects of cortic
respiratory distress induced by influenza virus, Journal of Microbiolog
j.jmii.2015.08.016investigation should be continued. Most of the observations
indicated that corticosteroid was a poor prognosis factor in
influenza virus infection,8,19 because corticosteroid was
significantly related to increased viral replication23 and
viral shedding, despite the use of antiviral therapy.24
However, we found that the influence of corticosteroid
administration was different in two alternate populations:
those with chronic lung disease and those with metabolic
syndrome. In patients with chronic lung disease, a corti-
costeroid was harmful (Figure 3) to them and early
administration of a corticosteroid was observed. Patients
with influenza infection are more likely to have acute
exacerbation of chronic obstructive pulmonary disease,25,26
early administration of a corticosteroid thus occurs in this
scenario. Second, immune dysfunction among patients with
chronic obstructive pulmonary disease results in a defi-
ciency in effective T cell responses against viral infection23
that resulted in poor prognosis.
Among patients without chronic lung disease, adminis-
tration of a systemic corticosteroid seemed to be a good
prognosis factor in patients with metabolic syndrome
(Figure S4), and the benefits remained if the patients were
infected with H1pdm09 and type B viruses. Although the
small sample size may result in statistical insignificance, it
hinted at the role of corticosteroid in different populations.
In patients with diabetes, obesity, hypertension, and
hyperlipidemia, there were higher probabilities of respira-
tory failure and mortality during H1pdm09 viral infec-
tion.20,27 Proinflammatory cytokines such as C-peptide,
procalcitonin, interleukin (IL)-6, interferon-gamma, and C-
reactive protein are also increased after H1pdm09 viral
infection.28,29 Pre-existing serum leptin levels were found
to be related to acute respiratory distress syndrome, and
this could be improved by antileptin or anti-IL-6 anti-
bodies.29 Impaired T-cell function against viral infection
and reduced interferon-gamma production after influenza
virus infection30,31 were also observed in obesity hosts.
Since glucocorticoids have an anti-inflammatory effect32 on
IL-6 and IL-833 in bronchial epithelial cells, this could
explain the observation and further study was considered.
Regarding the superinfection or colonization after 72
hours of hospitalization, the community acquired patho-
gens (i.e., Streptococcus spp, methicillin-sensitive Staphy-
lococcus aureus) were seldom observed. By contrast, most
patients were recorded with no bacteria or normal mixed
flora in sputum (60.4%, 29/48). The ventilator associated
methicillin-resistant S. aureus (MRSA) was only isolated in
one patient without mortality; by contrast, fatal
community-acquired MRSA pneumonia was usually observed
in other countries.34e37 The GNBs, usually to be considered
as nosocomial pathogens, were more frequently found in
the current study. Compatible with a previous study19,38,
this was associated with prolonged hospitalization and
possibly with a systemic corticosteroid (Table 4). However,
the all-cause mortality was unrelated to the GNBs, opposite
to the results of a retrospective survey.19 The in-
significances may be explained by heterogeneous comor-
bidities, limited sample size, administration of antibiotics,
and colonization rather than true infection. A further large
scaled survey is warranted.
The limitations of this study are as follows: (1) a lack of
virological evidence regarding viral mutation and NAIosteroid and neuraminidase inhibitors on survival in patients with
y, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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+ MODELsusceptibility; (2) a limited number of patients and a lack of
multivariable analysis, therefore, selection bias may be
present; (3) a retrospective study design with heteroge-
neous comorbidities and incomplete clinical data; and (4) a
lack of laboratory evidence of pro- and anti-inflammatory
cytokine profiles in different populations.
In conclusion, H1pdm09 and type B were the main ge-
notypes of influenza infection in patients with respiratory
distress from 2012 to 2014 in Taiwan, and salvage peramivir
treatment had a better prognosis than monotherapy with
oseltamivir. The early administration of medium-to-high
dose corticosteroid prior to or within 72 hours of antiviral
therapy was a significant risk factor for shorter survival
time. In addition, a systemic corticosteroid was related to
poor prognosis in patients with chronic lung disease.Conflicts of interest
The authors have no conflicts of interest to declare.References
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